SynthesisBMC medicine2022
Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.
Synthesis in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.The British journal of surgery · 2024Guideline
- The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome.BMC medicine · 2023Pooled it
- Body Mass Index and Risk of Female Reproductive System Tumors Subtypes: A Meta-Analysis Using Mendelian Randomization.Technology in cancer research & treatmentPooled it
- Trends and future projections of endometrial cancer burden attributable to high BMI in China: an age-period-cohort analysis based on 1990-2021 data.Journal of gynecologic oncology · 2026Article
- The Tumor Multi-Omic Landscape of Endometrial Cancers Developed on a Background of Adiposity.Genes · 2026Article
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- Article
- Review
- Obesity and cancer: Methodological frontiers for mechanistic discoveries.PLoS medicine · 2026Review
- Article
- Association Between Educational Attainment and the Risk of Gynecological Malignancies: A Mediation Mendelian Randomization Study.International journal of women's health · 2026Article
- Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.Journal of the National Cancer Institute · 2025Article
- When Should We Biopsy? A Risk Factor-Based Predictive Model for EIN and Endometrial Cancer.Cancers · 2025Article
- Predicted peptide scaffolds for drug screening in endometrial cancer organoids.Scientific reports · 2025Article
- Diagnostic role of galanin in distinguishing endometrial atypical hyperplasia and carcinoma from benign endometrial conditions.Scientific reports · 2025Article
- Obesity as a Catalyst for Endometrial Hyperplasia and Cancer Progression: A Narrative Review of Epidemiology, Molecular Pathways, and Prevention.Biomedicines · 2025Review
- Adiposity, metabolites and endometrial cancer risk: inference from combinations of Mendelian randomization and observational analyses.BMC cancer · 2025Observational
- Exploring irisin levels in patients with endometrial atypical hyperplasia and carcinoma: a comparative analysis.BMC cancer · 2025Article
- Unveiling the Causal Roles of the Oral Microbiome-Host Metabolism-Inflammation Axis in Periodontitis: A Mendelian Randomisation Study.Oral health & preventive dentistry · 2025Article
- The Effect of Circulating Proteins and Their Role in Mediating Adiposity's Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundEndometrial cancer is the most common gynaecological cancer in high-income countries. Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the molecular mechanisms underpinning this association remain unclear. We used Mendelian randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic and inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential mediating role of these molecular traits in the relationship between BMI and endometrial cancer using multivariable MR.
methodsGenetic instruments to proxy 14 molecular risk factors and BMI were constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated (P < 5.0 × 10
resultsIn MR analyses, there was strong evidence that BMI (OR per standard deviation (SD) increase 1.88, 95% CI 1.69 to 2.09, P = 3.87 × 10
conclusionsOur comprehensive MR analysis provides insight into potential causal mechanisms linking BMI with endometrial cancer risk and suggests targeting of insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.